Kynam Capital reports 5.84M-share (8.77%) position in Celldex (CLDX)
Kynam Capital has filed an amended Schedule 13G/A, disclosing a beneficial ownership of 5,840,567 shares of Celldex Therapeutics (CLDX), which represents an 8.77% stake in the company. The filing indicates shared voting and dispositive power for these shares among Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang. The amendment confirms a passive investment intent, noting the ownership snapshot as of the filing date.
Bellevue (CLDX) holds 1.2M shares (1.5%) — files Amendment No.1
Bellevue Group and its subsidiary, Bellevue Asset Management AG, have filed an Amendment No. 1 to their Schedule 13G/A for Celldex Therapeutics, Inc. (CLDX). This filing indicates that they now beneficially own 1.2 million shares, representing 1.5% of the common stock, a reduction that makes this an "exit filing" as their holdings are now below 5%. The report details their shared voting and dispositive power over these shares, calculating based on 78,492,072 shares outstanding.
State Street (CLDX) reports 2.8M shares, 4.2% stake in CELLDex Therapeutics
State Street Corporation has reported a beneficial ownership of 2,804,168 shares, representing a 4.2% stake in CELLDex Therapeutics. This disclosure, made via a Schedule 13G filing, indicates passive ownership and includes shared voting power over 2,620,053 shares and shared dispositive power over the full 2,804,168 shares. The filing lists several affiliated investment adviser entities as the reporting subsidiaries, confirming State Street's position as a large passive holder.
The Bull Case For Celldex Therapeutics (CLDX) Could Change Following Q1 Loss And Barzolvolimab Milestones
Celldex Therapeutics reported a significant Q1 2026 loss of US$78.69 million with revenue falling to US$15,000, yet simultaneously advanced its lead antibody barzolvolimab, completing Phase 3 enrollment six months early and raising US$345 million. This mixed financial report and clinical progress are reshaping Celldex's investment outlook, with attention on late-2026 CSU readouts and the balance between dilution and extended funding. Investors are advised to consider various viewpoints on valuation and potential risks.
LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $67
LifeSci Capital has reiterated its Buy rating for Celldex Therapeutics (CLDX.US), maintaining a target price of $67. This indicates a continued positive outlook on the company's stock performance from the analyst firm.
CLDX SEC Filings - Celldex Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Celldex Therapeutics Inc. (CLDX) SEC filings, including annual 10-K reports, quarterly 10-Q reports, 8-K material event disclosures, and insider trading forms. It highlights recent filings such as the Q3 2025 10-Q report detailing financial results and the 8-K filing regarding Phase 2 Barzolvolimab EoE results, alongside an insider stock sale. The platform offers AI-powered summaries to simplify understanding of these regulatory documents for investors.
Weighing Celldex Therapeutics (CLDX) Valuation As Price-To-Book And DCF Send Mixed Signals
Celldex Therapeutics (CLDX) has shown strong recent stock performance, with gains of 6.3% over the past month and 40.2% over three months. While its Price-to-Book (P/B) ratio of 5x suggests overvaluation compared to industry averages, a Discounted Cash Flow (DCF) model indicates the stock is undervalued, leading to mixed signals regarding its true valuation. Investors are advised to consider both the risks and potential upside, and to use various screening tools for further research.
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q1 Revenue $0.0M, Vs. FactSet Est of $795K
Celldex Therapeutics, Inc. (CLDX) reported Q1 revenue of $0.0 million, significantly missing FactSet's estimated revenue of $795,000. This indicates the company did not generate expected sales during the first quarter.
Celldex: Q1 Earnings Snapshot
Celldex Therapeutics Inc. reported a first-quarter loss of $78.7 million, or $1.18 per share, which was below Wall Street estimates. The biopharmaceutical company also posted revenue of $15,000, missing analyst expectations. This financial update was generated using data from Zacks Investment Research.
Celldex: Q1 Earnings Snapshot
Celldex Therapeutics Inc. (CLDX) reported a Q1 loss of $78.7 million, or $1.18 per share, which missed Wall Street expectations of a $1.10 per share loss. The biopharmaceutical company also reported revenue of $15,000, falling short of the $1.3 million forecast by analysts.
Celldex: Q1 Earnings Snapshot
Celldex Therapeutics Inc. reported a first-quarter loss of $78.7 million, or $1.18 per share, which fell short of analyst expectations. The company also posted revenue of $15,000, significantly missing Wall Street forecasts of $1.3 million.
Celldex Therapeutics (NASDAQ: CLDX) widens loss while funding late-stage barzolvolimab trials
Celldex Therapeutics reported a wider net loss of $78.7 million for Q1 2026, primarily due to increased research and development expenses for its lead antibody barzolvolimab. Despite the loss, the company secured approximately $323.9 million in net proceeds from an April 2026 public offering, extending its funding runway through 2028. Celldex is advancing multiple late-stage clinical trials for barzolvolimab, targeting chronic spontaneous urticaria, chronic inducible urticaria, prurigo nodularis, and atopic dermatitis, with key data readouts anticipated in late 2026.
Celldex (NASDAQ: CLDX) Q1 loss grows while $345M raise funds pipeline
Celldex Therapeutics reported a wider net loss of $78.7 million in Q1 2026, compared to $53.8 million a year earlier, primarily due to increased spending on its late-stage pipeline, particularly barzolvolimab. Despite the larger loss, the company strengthened its financial position with a $345 million public offering in April, extending its cash runway through 2028. Celldex also announced significant progress in its clinical programs, including the early completion of enrollment for Phase 3 chronic spontaneous urticaria studies of barzolvolimab and anticipated multiple data readouts in 2026.
Press Release: Celldex Reports First Quarter Financial Results and Provides Corporate Update
Celldex Therapeutics reported its first-quarter financial results for 2026, highlighting a net loss of $29.7 million and significant R&D expenses primarily due to its clinical programs, including the ongoing Phase 2 trial of barzolvolimab. The company maintained a strong cash position of $244.9 million, projected to fund operations into mid-2027, and provided updates on its clinical development pipeline. The report underscores Celldex's focus on advancing its lead therapeutic candidate, barzolvolimab, for various mast cell-driven diseases and its other preclinical programs.
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) reported a Q1 loss of $1.18 per share, missing the Zacks Consensus Estimate of a $1.1 loss and a year-ago loss of $0.81. The biopharmaceutical company also fell short on revenue, posting $0.02 million against an estimate of $1.77 million. Despite the disappointing quarter, Celldex's shares have risen 26.6% year-to-date, and the stock currently holds a Zacks Rank #2 (Buy).
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q1 Revenue $0.0M, vs. FactSet Est of $795K
Celldex Therapeutics, Inc. (CLDX) reported Q1 revenue of $0.0 million, falling short of FactSet's estimated $795K. The company is a clinical-stage biotechnology firm specializing in developing therapies for inflammatory, allergic, and autoimmune diseases. The article also mentions recent analyst upgrades and public stock offerings for Celldex Therapeutics.
Celldex: Q1 Earnings Snapshot
Celldex Therapeutics Inc. (CLDX) reported a first-quarter net loss of $78.7 million, or $1.18 per share, missing Wall Street expectations. The company also posted just $15,000 in revenue, significantly below analyst forecasts of $1.3 million.
Celldex: Q1 Earnings Snapshot
Celldex Therapeutics Inc. (CLDX) reported a first-quarter loss of $78.7 million, or $1.18 per share. This fell short of Wall Street estimates, which predicted a loss of $1.10 per share. The biopharmaceutical company also missed revenue forecasts, posting $15,000 against an expected $1.3 million.
FMR LLC reports 5.6% stake in CellDex Therapeutics (CLDX)
FMR LLC has filed an amended Schedule 13G/A, disclosing a 5.6% beneficial ownership stake in CellDex Therapeutics (CLDX), amounting to 3,749,048.03 shares. FMR LLC holds sole dispositive power over these shares, and Abigail P. Johnson is also listed with shared filing authority. This filing is informational, indicating a passive investment above the 5% threshold, and does not suggest immediate changes in company operations or future transactions.
Vanguard Capital Management (NASDAQ: CLDX) reports 3.45M shares; 5.17% stake
Vanguard Capital Management has disclosed a beneficial ownership of 3,446,795 shares, representing a 5.17% stake, in Celldex Therapeutics Inc (NASDAQ: CLDX) through a Schedule 13G filing. The filing indicates Vanguard's sole dispositive power over all these shares and sole voting power over 485,900 shares. This is a standard disclosure for institutional investors, and no transaction intentions are stated.
Celldex earnings on deck as barzolvolimab Phase 3 nears readout
Celldex Therapeutics Inc. is approaching its Q1 earnings report, with investor focus primarily on the progress of its pivotal drug trial for barzolvolimab, especially the upcoming Phase 3 readout. While analysts expect a loss of $1.19 per share and revenue of $875,000, the company's valuation largely hinges on this experimental antibody for chronic skin conditions. Investors will be keen for updates on trial conduct, data quality, and the timeline for Q4 2026 topline results, alongside cash deployment plans for commercial launch preparation and pipeline expansion.
[ARS] Celldex Therapeutics, Inc. SEC Filing
This article reports on Celldex Therapeutics, Inc.'s recent ARS SEC filing. The filing, dated April 29, 2026, concerns the company's annual report. Additional details about CLDX's stock performance and other recent SEC filings are also provided.
Celldex Therapeutics (NASDAQ:CLDX) Shares Pass Above 200 Day Moving Average - What's Next?
Celldex Therapeutics (NASDAQ:CLDX) shares recently moved above their 200-day moving average, reaching a high of $34.65 and closing at $33.66. This upward movement comes despite the company missing its recent quarterly earnings and analysts forecasting negative earnings for the fiscal year. Wall Street analysts currently have a "Moderate Buy" rating on CLDX with an average price target of $46.36, indicating a bullish sentiment despite fundamental challenges.
Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch
Celldex Therapeutics has priced a public offering of 10.3 million shares at $29 per share, aiming to raise $300 million. The company plans to use these proceeds to support the potential commercial launch of its drug barzolvolimab, which recently demonstrated positive results in chronic inducible urticaria (CInU) and cold urticaria studies. This capital raise follows a previous offering in February 2023.
Assessing Celldex Therapeutics (CLDX) Valuation After Strong Recent Share Price Gains
Celldex Therapeutics (CLDX) has seen significant share price gains recently, with a 76.6% return over the past year. While its Price-to-Book (P/B) ratio of 5.1x appears reasonable compared to peers, a Discounted Cash Flow (DCF) model suggests the stock might be significantly undervalued at $79.92 per share compared to its current price of $34.25, despite the company's unprofitability and early-stage pipeline risks. Investors are encouraged to review the details and consider both the potential rewards and warning signs.
Barclays upgrades Celldex Therapeutics (CLDX)
Barclays has upgraded Celldex Therapeutics (CLDX). The investment bank announced the upgrade, signaling a more positive outlook on the biopharmaceutical company. Further details on the reasons for the upgrade were not immediately available in the provided content.
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up Following Analyst Upgrade
Celldex Therapeutics (NASDAQ:CLDX) saw its shares gap up after Barclays upgraded the stock from "underweight" to "overweight," raising its price target to $45.00. This upgrade follows a significant earnings miss where the company reported a loss of $1.22 EPS against an estimated -$1.00 and notably low revenue. Despite mixed analyst coverage, the consensus remains a "Moderate Buy" for CLDX.
Barclays Upgrades Celldex Therapeutics to Overweight From Underweight, Adjusts Price Target to $45 From $24
Barclays has upgraded Celldex Therapeutics (CLDX) from Underweight to Overweight, significantly raising its price target from $24 to $45. This upgrade reflects a positive outlook on the biopharmaceutical company, which focuses on developing therapeutics for mast cell-mediated diseases. The article also notes recent activities including a public offering of shares and positive Phase 2 data for its drug Barzolvolimab.
Barclays upgrades Celldex stock rating on trial enrollment progress By Investing.com
Barclays has upgraded Celldex Therapeutics (NASDAQ:CLDX) to Overweight from Underweight and increased its price target to $45 due to significantly increased confidence in the success of the company's Phase 3 program. This upgrade is largely driven by rapid enrollment in the EMBARQ trial, which completed six months ahead of schedule, suggesting strong demand and potential for successful Phase 3 results for barzolvolimab in chronic spontaneous urticaria and prurigo nodularis. The firm also raised its probability of success and peak revenue estimates for both chronic spontaneous urticaria and chronic inducible urticaria.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts
Celldex Therapeutics (NASDAQ:CLDX) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $44.45. While some analysts like Wolfe Research and Stifel Nicolaus have upgraded or raised targets, Goldman Sachs maintains a "neutral" rating and Weiss Ratings a "sell." The company recently reported a quarterly EPS miss, and analysts anticipate a loss of -$2.48 per share for the current year.
Celldex Therapeutics stock hits 52-week high at 34.55 USD
Celldex Therapeutics (CLDX) stock has reached a new 52-week high of $34.55, marking an 85.03% increase over the past year. The biotech company has a strong financial position with a current ratio of 10.49 and more cash than debt, driven by advancements in its therapies. Additionally, recent news highlights a successful public offering netting approximately $345 million and positive Phase 2 trial results for barzolvolimab, which improved quality of life for urticaria patients.
CLDX: Barzolvolimab shows strong, durable efficacy in urticaria with pivotal phase III data due Q4
Celldex Therapeutics' (CLDX) drug Barzolvolimab shows promising rapid, durable, and high complete response rates in urticaria, with Phase III data expected in Q4. The company is well-funded and strategically positioned for both first- and second-line advanced therapy markets, including a promising pipeline drug, CDX-622. This information is based on an H.C. Wainwright conference audio transcript from April 14, 2026.
Tudor Investment Corp ET AL Makes New $818,000 Investment in Celldex Therapeutics, Inc. $CLDX
Tudor Investment Corp ET AL initiated a new position in Celldex Therapeutics (NASDAQ:CLDX) during the third quarter, purchasing 31,618 shares valued at approximately $818,000. Several other institutional investors also acquired stakes in the biopharmaceutical company. Despite these investments, Celldex Therapeutics reported a Q4 EPS of ($1.22) and revenue of $0.12 million, missing analyst estimates, and analysts have mixed but generally positive ratings with an average target price of $44.45.
Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment
Celldex Therapeutics (NASDAQ: CLDX) recently highlighted its promising drug barzolvolimab, an anti-KIT monoclonal antibody, which is in late-stage development for chronic urticaria and other inflammatory skin diseases. The company announced that its Phase III chronic spontaneous urticaria (CSU) program enrolled approximately 1,900 patients six months ahead of schedule, with top-line results expected in Q4 2026. Barzolvolimab works by depleting mast cells, offering a novel mechanism compared to existing therapies, with Phase II data showing rapid, profound, and durable complete response rates in CSU patients.
Celldex to Present at Upcoming Investor Conference
Celldex (NASDAQ:CLDX) announced that its management will participate in a fireside chat at H.C. Wainwright's 4th Annual Inflammatory Skin Disease Virtual Conference. The event is scheduled for Tuesday, April 14, at 3:30 pm ET. The news was provided by GlobeNewswire.
Celldex will stream April 14 fireside chat from skin disease event
Celldex (NASDAQ: CLDX) announced that its management will participate in a fireside chat at H.C. Wainwright’s 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026, at 3:30 pm ET. A live webcast of the presentation will be available on the company's Investors section, with replays accessible for 90 days. The event will focus on developments in inflammatory skin diseases.
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Celldex Therapeutics announced the closing of its public offering of common stock, including the full exercise of the underwriters' option to purchase additional shares. The company sold 11,896,750 shares at $29.00 per share, generating approximately $345 million in gross proceeds. Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor acted as joint bookrunning managers for the offering.
A Look At Celldex Therapeutics (CLDX) Valuation After Equity Raise And New Barzolvolimab Data
Celldex Therapeutics recently raised $345 million through an equity offering and released new Phase 2 barzolvolimab data. Despite its current P/B ratio appearing in line with peers, a discounted cash flow model suggests the stock might be significantly undervalued. The article advises investors to assess the company's valuation, considering both potential rewards and warning signs.
Precision Trading with Celldex Therapeutics Inc. (CLDX) Risk Zones
This article provides a detailed analysis of Celldex Therapeutics Inc. (CLDX), highlighting a near-term neutral sentiment amidst mid and long-term strength. It outlines various AI-generated trading strategies, including position, momentum breakout, and risk hedging, complete with entry, target, and stop-loss zones. The analysis also covers multi-timeframe signal strengths, support, and resistance levels for effective precision trading.
Celldex Therapeutics Closes $345M Public Stock Offering
Celldex Therapeutics, a clinical-stage biotech company, has closed a $345 million public stock offering, including the full exercise of the underwriters' option to purchase additional shares. The company sold nearly 12 million shares at $29 each, resulting in gross proceeds of approximately $345 million. Celldex plans to use these funds to advance its pipeline of antibody-based treatments for severe inflammatory, allergic, and autoimmune diseases, demonstrating investor confidence in its immune-based therapies.
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Celldex Therapeutics announced the closing of its underwritten public offering of 11,896,750 shares of common stock, including the full exercise of the underwriters' option to purchase additional shares, at $29.00 per share. The offering generated gross proceeds of approximately $345 million for Celldex. Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor served as joint bookrunning managers.
Celldex sells nearly 11.9M shares, raises $345M in stock deal
Celldex Therapeutics announced the closing of its underwritten public offering, selling 11,896,750 common shares, including the full exercise of the underwriters' option for additional shares. The sale, priced at $29.00 per share, generated approximately $345 million in gross proceeds for the company. This financing operation finalizes a capital raise process that began in early April 2026.
Celldex Therapeutics Completes $345 Million Public Offering of Common Stock
Celldex Therapeutics announced the completion of its public offering, raising approximately $345 million from the sale of 11.9 million shares at $29 each. The offering, which included the full exercise of the underwriters' option, significantly boosts Celldex's financial position to advance its clinical programs. While providing substantial funding, this also results in dilution for existing shareholders.
Celldex Therapeutics Completes $345 Million Public Offering of Common Stock
Celldex Therapeutics has successfully closed its underwritten public offering, raising approximately $345 million in gross proceeds from the sale of 11,896,750 shares of common stock at $29.00 per share. This includes the full exercise of the underwriters' option for additional shares, reflecting strong market demand. The offering provides significant funding for Celldex, a biotechnology company focused on developing therapeutics for severe inflammatory, allergic, autoimmune, and other diseases.
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Celldex Therapeutics announced the closing of its underwritten public offering, which included the full exercise of the underwriters' option to purchase additional shares. The company sold 11,896,750 shares of common stock at $29.00 per share, generating approximately $345 million in gross proceeds. Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor served as joint bookrunning managers for the offering.
Celldex Therapeutics Announces Closing of Public Offering
Celldex Therapeutics announced the closing of its underwritten public offering of 11,896,750 shares of common stock, which included the full exercise of the underwriters’ option to purchase additional shares. The gross proceeds from the offering totaled approximately $345 million. Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor acted as joint bookrunning managers.
Celldex Therapeutics Announces Closing of Public Offering
Celldex Therapeutics announced the closing of its previously declared public offering of 11,896,750 shares of common stock, which includes the full exercise of the underwriters' option to purchase additional shares. The shares were offered at $29.00 each, generating approximately $345 million in gross proceeds for Celldex. The offering was managed by Leerink Partners, TD Cowen, Guggenheim Securities, Cantor, LifeSci Capital, and H.C. Wainwright & Co.
Did Celldex’s (CLDX) US$300 Million Equity Raise to Fund Barzolvolimab Just Shift Its Investment Narrative?
Celldex Therapeutics recently completed a US$300 million equity raise to fund the launch preparation and development of barzolvolimab, a drug with promising Phase 2 data for chronic urticaria. This capital infusion strengthens Celldex's financial position ahead of Phase 3 results, reducing near-term financing risk, but also adds to shareholder dilution. The company's investment narrative now heavily relies on barzolvolimab's successful commercialization and pipeline expansion.
Celldex Therapeutics announces public offering of common stock
The article states that Celldex Therapeutics has announced a public offering of its common stock. No further details about the offering size, terms, or intended use of proceeds are provided in the current content.
JPMorgan Chase & Co. Sells 49,046 Shares of Celldex Therapeutics, Inc. $CLDX
JPMorgan Chase & Co. reduced its stake in Celldex Therapeutics (NASDAQ:CLDX) by 21% in the third quarter, selling 49,046 shares but still holding 184,775 shares valued at $4.78 million. Despite this, other institutions like Wellington Management Group, Vestal Point Capital, and Eventide Asset Management significantly increased their positions in the biopharmaceutical company. Celldex Therapeutics recently missed earnings and revenue estimates, yet analysts maintain a "Moderate Buy" rating with a consensus price target of $44.45.
